Keystone Heart has started distributing Ireland-based Vasorum’s Celt ACD vascular closure device in the U.S. and Europe, effective this month.
Approved by FDA in 2016, the Celt ACT is a biocompatible implant meant to close femoral artery punctures taking place after catheterization. Health providers have implanted the CeltACT in more than 40,000 patients to date.
“The Keystone Heart Ltd. agreement is validation that the Celt ACD vascular closure device has proven itself to be a market leading arterial puncture closure device that allows rapid and complete hemostasis independent of vascular anatomy, including calcified arteries,” Jim Coleman, Vasorum’s co-founder and CEO, said in a news release yesterday.
“This partnership provides an opportunity to accelerate growth for both companies, while serving both clinicians and patients worldwide,” Coleman said.
The distribution agreement build’s on Keystone Heart’s structural heart foundation, said Keystone Heart CEO Chris Richardson.
Headquartered in Israel with U.S. operations in Tampa, Fla., Keystone Heart merged with Chinese transcatheter heart valve company Venus Medtech at the end of 2018.